Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elotuzumab + bortezomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
**Elotuzumab + bortezomib + dexamethasone** is a three-drug combination regimen used in the treatment of relapsed or refractory multiple myeloma. **Elotuzumab** is a humanized monoclonal antibody that targets the Signaling Lymphocytic Activation Molecule F7 (SLAMF7), activating natural killer (NK) cells and facilitating antibody-dependent cell-mediated cytotoxicity against myeloma cells. **Bortezomib** is a small molecule proteasome inhibitor that blocks the 26S proteasome, leading to apoptosis of cancer cells. **Dexamethasone** is a synthetic glucocorticoid corticosteroid that exerts anti-inflammatory and immunosuppressive effects. This regimen is designed to leverage direct cytotoxic effects (bortezomib, dexamethasone) and immune-mediated mechanisms (elotuzumab) for improved disease control. Primary indication: relapsed/refractory multiple myeloma[4][6].
- Other names
- EBd
02
Targets
GR (Glucocorticoid receptor)SLAMF7 (Signaling lymphocytic activation molecule family member 7)26S proteasome
Beyond the preview
Go deeper on elotuzumab + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elotuzumab + bortezomib + dexamethasone.